CEO Update - 4 December 2023

UK Genomics success

UK Biobank is a British success story that puts us at the heart of a key global technology of this century. Last week, UK Biobank published the world’s largest collection of full human genomes. Set up 20 years ago, the charity UK Biobank recruited half a million altruistic volunteers to create the world’s most comprehensive source of health data. It can now be used by researchers across the world, from academic, commercial, government and charitable settings, for scientific discoveries that improve human health.

Professor Sir Rory Collins FRS FMedSci, Principal Investigator of UK Biobank captured the importance of the project well when he said: “Scientists are looking at UK Biobank  like Google Maps when they want to know what are the pathways from lifestyle, environment, genetics to disease, they don’t go to Google, they go to UK Biobank.” Our genomic heritage allied with our capacity to turn that into useful and productive research product is a core part of the UK’s sustainable competitive advantage in life sciences. Congratulations to all who have contributed to its success.

Engaging with the Labour Opposition 

Keir Starmer reshuffled his shadow ministers last week, with Chris Evans joining Peter Kyle’s shadow DSIT team as Shadow Minister for Tech and Digital Economy. Steve McCabe, a champion for our sector who has engaged extensively with the BIA, also joined the shadow frontbench. We continue to engage with the Labour Party in the run-up to the next general election.

Dr Martin Turner, Head of Policy and Public Affairs at BIA, spoke on behalf of members at the HSBC Innovation Banking breakfast meeting with Shadow Chancellor Rachel Reeves and Shadow Science Secretary Peter Kyle last week. Martin highlighted the importance of R&D tax reliefs to life science SMEs and explained how a future Labour government could unlock institutional investment from pension funds. Rachel and Peter were very receptive to Martin and other BIA members present in the meeting. It’s been great to see Labour engaging with these key issues for UK life sciences. 

Finance Bill published with R&D tax credit changes

The Finance Bill, which provides the legal basis needed for announcements in the Autumn Statement, has been published with the R&D tax relief changes. In case you've missed it, see our webinar explaining the changes. The BIA Finance and Tax Committee (FTAC) chair Colin Hailey gave evidence to the House of Lords committee, making the case for year-on-year flexibility – or a period of grace as it is described – that is a win for the sector and is now in the Government’s proposals to parliament.

Understanding the VPAG deal 

The ABPI are holding another webinar to explain the Voluntary scheme for branded medicines Pricing, Access and Growth (VPAG) on Wednesday this week, and another on Friday, 15 December. On 15 December, the Department of Health will attend and answer questions on both the new VPAG and statutory scheme; to register, click here. Both these webinars are all industry.

Flagship Pioneering into the UK

It was a pleasure to join BIA member Flagship Pioneering as they launched their London base, signing a Memorandum of Understanding with the UK government last Tuesday. It sets out five ways the two can work closely together to maximise the UK’s potential to turn bright new ideas into thriving life science businesses. This includes working together on UK-based clinical trials and clinical delivery; looking into potential locations in the UK to host manufacturing sites for Flagship’s life sciences companies; engaging with UK’s world-leading genomics organisations, such as Genomics England, NIHR BioResource and UK Biobank; and Flagship feeding into the UK’s horizon scanning processes that aim to identify opportunities for innovation, earlier.  

Flagship demonstrated its commitment to the UK earlier this month with the $50 million launch of Quotient Therapeutics, their first-ever company co-anchored in both the US and UK. The firm is pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. 

Race against resistance – BBC AMR production

Thank you to the BBC for hosting a timely AMR event focused on their work to raise awareness of this silent pandemic. The full version is now available on YouTube – although sadly we will not see the programme on UK channels since it is produced by BBC StoryWorks, the division of the BBC that produces content aimed at global rather than domestic audiences. 

Great bioProcessUK in Brighton last week

Thank you to all who attended bioPorcessUK last week in Brighton. It was great to share and celebrate with the biomanufacturing community. I was struck by the atmosphere of infectious enthusiasm and I was particularly taken by the strength of the next generation coming into the sector highlighted by the student poster exhibitions and the Dragon's Den competition. If you weren’t able to make it you can capture some of the essence of a great three days through our latest blog.

Growing the pool of Diverse NEDs for life sciences

How do we grow a broader pool of talented non-executive directors (NED) in the UK, and what can we learn from those who have established themselves successfully? In association with the Diverse Directors' Programme (a collaboration between Start Codon and RBW Consulting), we'll discuss the challenges, explore solutions and, as always, hear from some incredible women leading the way in our sector at our final Women in Biotech of the year this Thursday – which is yet again sold out and as such has the hallmarks of being a great evening.

Only two more of these until Christmas!

All the best

Steve  

 

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

CEO Update - 20 February 2024

I'm looking forward to the BIA Committee Summit this week. It will be great to see 200 members in Westminster at one of the most lively and insightful events we do each year. I know it's the volunteer expert army that gives the BIA its unique impact with government and it's always great to understand the committee's priorities and the ideas at the intersection between committees that arise from the event.

Beyond health: why BIA is championing the biorevolution 

The BIA has named this frontier of science Deep Biotech. Our brand-new report, "Deep Biotech: Disruptive innovation for global sustainability" highlights how deep biotech is key to creating a sustainable UK bioeconomy and making the UK a science superpower that benefits all. 

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

Recent decision from the EPO smooths the way to obtaining patents in Europe

The BIA’s Intellectual Property Advisory Committee (IPAC) helps BIA understand and shape the environment for IP ownership to ensure strong protection for BIA member companies. Our EU policy subcommittee has taken a look at what a recent European decision means for the right to claim priority to an earlier filed patent application. This blog sets out some of the details of the case, and the practical implications for BIA members.​​​​​​​

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

CEO Update - 12 February 2024

It was great to see the hugely positive response we’ve had to the launch of our new report "Deep Biotech: Disruptive innovation for global sustainability". I believe we're on the cusp of a biorevolution powered by Deep Biotech, and I want our Association at the forefront of shaping the future of Deep Biotech and championing its disruptive potential.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Enter the dragon: Exploring China’s life sciences market

Next week, Chinese people across the world will be celebrating Chinese New Year. This is the “year of the dragon”, a symbol of strength for the Chinese people. It also represents prosperity, a value Chinese strive for across aspects of life, society and business.

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

More within